Innate Pharma H1 EPS €(0.31) Down From €0.02 YoY, Sales €12.345M Down From €40.198M YoY
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma reported a significant decline in its H1 earnings per share (EPS) and sales compared to the previous year. The EPS dropped from €0.02 to €(0.31), and sales decreased from €40.198 million to €12.345 million. Despite this, the company maintains a cash position of €102.1 million as of June 30, 2024, with an anticipated cash runway until the end of 2025.
September 12, 2024 | 6:08 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Innate Pharma's H1 financial results show a significant decline in EPS and sales year-over-year. The EPS fell from €0.02 to €(0.31), and sales dropped from €40.198 million to €12.345 million. However, the company has a strong cash position of €102.1 million, providing a runway until the end of 2025.
The significant decline in EPS and sales is likely to negatively impact investor sentiment and the stock price in the short term. However, the strong cash position provides some financial stability, which may mitigate the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100